Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Selvita S.A.
Headquarters:
Krakow, Poland
Website:
http://www.selvita.com
Year Founded:
2007
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Boguslaw Sieczkowski, MBA
Number Of Employees:
969
Enterprise Value:
$269,531,504
PE Ratio:
-105.06
Exchange/Ticker 1:
Warsaw:SLV
Exchange/Ticker 2:
N/A
Latest Market Cap:
$169,919,571
BioCentury
|
Jul 26, 2019
Company News
Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more
Read More
BioCentury
|
Feb 16, 2019
Emerging Company Profile
NodThera: Inhibiting the inflammasome for NASH
How NodThera is tackling NASH with NLRP3 inflammasome inhibitors
Read More
BioCentury
|
Jan 18, 2019
Targets & Mechanisms
Exploring 3-D genomic white space
How 3-D chromatin structures open up a higher level of gene regulation control
Read More
BioCentury
|
Jun 29, 2018
Financial News
Sofinnova Partners, 5AM lead £28 million NodThera series A
Read More
BioCentury
|
Jun 29, 2018
Finance
Nailing down NLRP3
Why investors backed $37M series A for inflammasome play NodThera
Read More
BioCentury
|
Jun 25, 2018
Financial News
Sofinnova Partners, 5AM lead £28 million NodThera series A
Read More
BioCentury
|
Sep 20, 2017
Distillery Therapeutics
Inflammation
Read More
BioCentury
|
Aug 9, 2017
Distillery Therapeutics
Neurology
Read More
BioCentury
|
May 3, 2017
Distillery Therapeutics
Gastrointestinal
Read More
BioCentury
|
Mar 31, 2017
Company News
Selvita, Menarini deal
Read More
Items per page:
10
1 - 10 of 22